New drug combo targets mysterious cancers

NCT ID NCT06754501

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining two immunotherapy drugs, atezolizumab and tiragolumab, can help control cancers of unknown primary (CUP) — cancers where doctors cannot find where the cancer started. Only 4 participants who have already tried chemotherapy are enrolled. The study focuses on safety and whether the tumors shrink or stop growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Atezolizumab and Tiragolumab (immune checkpoint inhibitors given by vein)
What this could lead to: If it works, this could point toward a new treatment option for people with cancer of unknown primary who have run out of standard options.
What could go wrong: This is a very small, early-phase trial with only 4 participants, so results may not apply widely. The drug combination may cause immune-related side effects and may not control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer cancer of unknown primary site neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.